Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Sionna Therapeutics, Inc.NASDAQ: SION
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$26.63M, compared with -$16.05M a year earlier. Trailing-twelve-month EBITDA was -$81.06M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -22.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$26.63M-58.9% QoQ
- Last fiscal yearDec 2025
- -$74.62M-22.3% YoY
- LTMMar 2026
- -$81.06M-24.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -65.9% | +100.0% | +165.9 pp |
| 1 year | -22.3% | +100.0% | +122.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (74.62M) USD
- Year-over-year change
- -22.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (74.62M) | -22.3% |
| FY2024 | 2024-12-31 | (61.02M) | -30.7% |
| FY2023 | 2023-12-31 | (46.68M) | -16.4% |
| FY2022 | 2022-12-31 | (40.12M) | — |
EBITDA vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 EBITDA of -$81.06M is the 4th highest of the 11 companies compared; the peer median is -$129.08M.
- Its year-over-year change of -24.0% is the 6th highest of 11, against a peer median of -14.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $57.08M | +205.8% | — | 21.5% | |
| LTM Mar 2026 | $46.13M | +1163.1% | — | 14.7% | |
| LTM Mar 2026 | -$25.52M | +9.6% | — | 6.0% | |
| LTM Mar 2026 | -$81.06M | -24.0% | — | — | |
| LTM Mar 2026 | -$112.45M | -48.6% | — | 520.3% | |
| LTM Mar 2026 | -$119.51M | -312.9% | — | 597.6% | |
| LTM Sep 2026 | -$138.65M | +34.7% | — | 204.3% | |
| LTM Sep 2026 | -$284.54M | -45.7% | — | — | |
| LTM Sep 2026 | -$305.37M | -38.1% | — | 272652.7% | |
| LTM Jun 2026 | -$393.82M | -87.1% | — | — | |
| LTM Jun 2026 | -$574.94M | +24.1% | — | — | |
| Peer median (excluding SION) | -$129.08M | -14.2% | — | 204.3% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 647K |
| Gross Profit | 0 | 0 | (668K) | (647K) |
| Gross Margin | — | — | — | — |
| Research & Development | 34.61M | 40.63M | 57.29M | 60.26M |
| Selling, General & Admin | 6.77M | 9.71M | 13.27M | 28.72M |
| Operating Expenses | 41.37M | 50.33M | 69.89M | 88.34M |
| Depreciation & Amortization | 122K | 583K | 668K | 647K |
| EBITDA | (40.12M) | (46.68M) | (61.02M) | (74.62M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (41.37M) | (50.33M) | (70.56M) | (88.98M) |
| Operating Margin | — | — | — | — |
| Interest Income | 1.13M | 2.77M | 8.17M | 13.3M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.13M | 3.07M | 8.87M | 13.71M |
| Income Before Tax | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.91) | (1.07) | (1.40) | (1.88) |
| EPS (Diluted) | (0.91) | (1.07) | (1.40) | (1.88) |
| Weighted Avg Shares | 44.12M | 44.12M | 44.12M | 39.96M |
| Weighted Avg Shares (Diluted) | 44.12M | 44.12M | 44.12M | 39.96M |
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.